Mildly Elevated Liver Transaminase Levels in the Asymptomatic Patient



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2005 Mar 15;71(6):1105-1110.

Mild elevations in liver chemistry tests such as alanine transaminase and aspartate transaminase can reveal serious underlying conditions or have transient and benign etiologies. Potential causes of liver transaminase elevations include viral hepatitis, alcohol use, medication use, steatosis or steatohepatitis, and cirrhosis. The history should be thorough, with special attention given to the use of medications, vitamins, herbs, drugs, and alcohol; family history; and any history of blood-product transfusions. Other common health conditions, such as diabetes, heart disease, and thyroid disease, can cause or augment liver transaminase elevations. The recent American Gastroenterological Association guideline regarding the evaluation and management of abnormal liver chemistry tests proposes a practical, algorithmic approach when the history and physical examination do not reveal the cause. In addition to liver chemistries, an initial serologic evaluation includes a prothrombin time; albumin; complete blood count with platelets; hepatitis A, B, and C serologies; and iron studies. Depending on the etiology, management strategies may include cessation of alcohol use, attention to medications, control of diabetes, and modification of lifestyle factors such as obesity. If elevations persist after an appropriate period of observation, further testing may include ultra-sonography and other serum studies. In some cases, biopsy may be indicated.

Hepatic transaminase tests such as alanine transaminase (ALT) and aspartate transaminase (AST) often are part of standard laboratory panels in asymptomatic outpatients, similar to screening tests for blood donors and for life insurance applicants. The evaluation of an abnormal ALT or AST level in an asymptomatic patient therefore is a common challenge encountered by primary care physicians.

According to the American Gastroenterological Association (AGA), 1 to 4 percent of the asymptomatic population may have elevated serum liver chemistries.1 This is consistent with the usual definition of an elevated transaminase level of the top 2.5 percent of the population range. Although one study2 of 19,877 asymptomatic young Air Force trainees found that only 0.5 percent had elevated ALT levels, physicians who have more patients with obesity, diabetes, and hyperlipidemia will have to address this issue more often.

Given the frequency of this problem, physicians should develop an informed approach to the investigation of transaminase elevations. An audit of primary care practices found that these abnormalities are not always investigated appropriately and that opportunities to intervene in treatable cases sometimes are missed.3 No controlled clinical trials have compared approaches to the management of abnormal transaminase levels. However, the AGA recently published a technical review1 and a position statement4 on the evaluation of liver chemistry tests. This article reviews the interpretation of ALT and AST levels and summarizes the AGA recommendations on addressing reported elevations.

Strength of Recommendations

Key clinical recommendation Label References

An algorithmic approach to evaluating mildly abnormal liver functions is recommended.

C

1

In the asymptomatic patient with negative serum testing and mild transaminase elevations, a period of lifestyle modification can be tried.

C

1

If abnormalities persist at the six-month follow-up visit, an ultrasonography of the liver is the recommended imaging modality.

C

1

ALT and AST are not useful screening tests in an otherwise healthy population.

C

1,10

The AST/ALT ratio is only somewhat helpful in diagnosis.

C

5,7


ALT = alanine transaminase; AST = aspartate transaminase.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, opinion, or case series. See page 1046 for more information.

Strength of Recommendations

View Table

Strength of Recommendations

Key clinical recommendation Label References

An algorithmic approach to evaluating mildly abnormal liver functions is recommended.

C

1

In the asymptomatic patient with negative serum testing and mild transaminase elevations, a period of lifestyle modification can be tried.

C

1

If abnormalities persist at the six-month follow-up visit, an ultrasonography of the liver is the recommended imaging modality.

C

1

ALT and AST are not useful screening tests in an otherwise healthy population.

C

1,10

The AST/ALT ratio is only somewhat helpful in diagnosis.

C

5,7


ALT = alanine transaminase; AST = aspartate transaminase.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, opinion, or case series. See page 1046 for more information.

Markers of Hepatic Injury and Necrosis

ALT and AST are two of the most reliable markers of hepatocellular injury or necrosis. Their levels can be elevated in a variety of hepatic disorders. Of the two, ALT is thought to be more specific for hepatic injury because it is present mainly in the cytosol of the liver and in low concentrations elsewhere. AST has cytosolic and mitochondrial forms and is present in tissues of the liver, heart, skeletal muscle, kidneys, brain, pancreas, and lungs, and in white and red blood cells. AST is less commonly referred to as serum glutamic oxaloacetic transaminase and ALT as serum glutamic pyruvic transaminase.

Although levels of ALT and AST can be extremely elevated (exceeding 2,000 U per L in cases of hepatocyte injury and necrosis related to drugs, toxins, ischemia, and hepatitis), elevations less than five times the upper limit of normal (i.e., about 250 U per L and below) are much more common in primary care medicine. The range of possible etiologies at this level of transaminase elevation is broader (Table 15,6) and the tests less specific. It also is important to recall that patients with normal ALT and AST levels can have significant liver disease in the setting of chronic hepatocyte injury (e.g., cirrhosis, hepatitis C).

TABLE 1

Etiology of ALT or AST Elevations When Less Than Five Times Normal

Common hepatic causes

Alcohol

Cirrhosis

Hepatitis B (chronic)

Hepatitis C (chronic)

Steatosis/steatohepatitis

Medications/toxins

Acute viral hepatitis

Less common hepatic causes

Autoimmune hepatitis

Hemochromatosis

Alpha1-antitrypsin deficiency

Wilson’s disease

Nonhepatic causes

Celiac disease

Hemolysis

Myopathy

Hyperthyroidism

Strenuous exercise

Macro-AST


ALT = alanine transaminase; AST = aspartate transaminase.

Adapted with permission from Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342:1267, with additional information from reference 5.

TABLE 1   Etiology of ALT or AST Elevations When Less Than Five Times Normal

View Table

TABLE 1

Etiology of ALT or AST Elevations When Less Than Five Times Normal

Common hepatic causes

Alcohol

Cirrhosis

Hepatitis B (chronic)

Hepatitis C (chronic)

Steatosis/steatohepatitis

Medications/toxins

Acute viral hepatitis

Less common hepatic causes

Autoimmune hepatitis

Hemochromatosis

Alpha1-antitrypsin deficiency

Wilson’s disease

Nonhepatic causes

Celiac disease

Hemolysis

Myopathy

Hyperthyroidism

Strenuous exercise

Macro-AST


ALT = alanine transaminase; AST = aspartate transaminase.

Adapted with permission from Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342:1267, with additional information from reference 5.

The ratio of AST to ALT has some clinical utility, but has important limitations. In many forms of acute and chronic liver injury or steatosis (fatty infiltration of the liver), the ratio is less than or equal to 1. This is particularly true in patients with hepatitis C. However, an AST/ALT ratio greater than 2 characteristically is present in alcoholic hepatitis. A recent study7 of 140 patients with nonalcoholic steatohepatitis (NASH; confirmed by liver biopsy) or alcoholic liver disease found a mean AST/ALT ratio of 0.9 in patients with NASH and 2.6 in patients with alcoholic liver disease. Within the population studied, 87 percent of patients with an AST/ALT ratio of 1.3 or less had NASH (87 percent sensitivity, 84 percent specificity). The severity of NASH as measured by the degree of fibrosis increased, as did the AST/ALT ratio. A mean ratio of 1.4 was found in patients with cirrhosis related to NASH. Wilson’s disease, a rare problem, can cause the AST/ALT ratio to exceed 4.5 While these ratios are suggestive of certain conditions, there is too much overlap between groups to rely on them exclusively when making a diagnosis.

Lactate dehydrogenase (LDH) is a less specific marker of hepatocellular necrosis and usually does not add diagnostic information to that obtained with ALT and AST testing. An exception to this is the transient but massive rise of LDH in cases of ischemic hepatitis and its sustained elevation that, along with elevated alkaline phosphatase levels, suggests malignant infiltration of the liver.5

Elevations of ALT and AST are not exclusive to liver pathology. Hyperthyroidism has been found in several studies to increase serum levels of liver enzymes including ALT and AST.8 Genetic influences on the level of ALT also are possible. A study9 of Danish twins showed that genetic factors accounted for 33 to 66 percent of the variation in ALT, gamma glutamyl transpeptidase, LDH, and bilirubin in patients 73 to 94 years of age. The AGA technical review states that serum ALT has diurnal variation, may vary day to day, and may be affected by exercise. It also notes that serum AST may be 15 percent higher in black men than white men.1

Another cause of elevated liver transaminase levels is muscle injury. Strenuous exercise or myopathy can cause elevations (especially of AST) without causing any other symptoms. A creatine kinase or other muscle marker can be obtained to confirm or exclude such a process.

Annual screening of healthy, asymptomatic patients for liver disease using ALT and AST levels is not useful. A Japanese study10 assessed the accuracy of ALT and AST for detecting hepatitis C, excess alcohol use, and fatty liver disease in male bank employees and found the positive predictive value of the test to be low. Only 3.9 percent of the men with an abnormal ALT level had hepatitis C; 8 percent were excessive users of alcohol; and 35.7 percent had fatty liver.

Management

A thorough medical history and physical examination are the cornerstone of the evaluation of patients with mildly elevated liver transaminase levels.1  The history should attempt to identify risk factors for disease, with special attention directed toward family history, medications, vitamins, herbal supplements, drug use, alcohol use, abnormal liver testing, blood-product transfusions, and symptoms of liver disease. Table 26 lists selected medications and herbal supplements that may cause elevated transaminase levels. Physicians should ask patients directly about their use of illicit drugs, herbal supplements, and other alternative “supplements” because these sometimes are omitted from the patient’s initial response to questions.

TABLE 2

Common Agents That Can Cause Liver Transaminase Elevations

Medications Herbal supplements/vitamins

Acetaminophen

Chaparral leaf

Amiodarone (Cordarone)

Ephedra

Amoxicillin-clavulanic acid

Gentian

Carbamazepine (Tegretol)

Germander

Fluconazole (Diflucan)

Jin bu huan

Glyburide (Micronase)

Kava

Heparin

Scutellaria (skullcap)

Isoniazid (INH)

Senna

Ketoconazole (Nizoral)

Shark cartilage

Labetalol (Normodyne)

Vitamin A

Nitrofurantoin (Furadantin)

Nonsteroidal anti-inflammatory drugs

Phenytoin (Dilantin)

Protease inhibitors

Sulfonamides

Trazodone (Desyrel)


Information from reference 6.

TABLE 2   Common Agents That Can Cause Liver Transaminase Elevations

View Table

TABLE 2

Common Agents That Can Cause Liver Transaminase Elevations

Medications Herbal supplements/vitamins

Acetaminophen

Chaparral leaf

Amiodarone (Cordarone)

Ephedra

Amoxicillin-clavulanic acid

Gentian

Carbamazepine (Tegretol)

Germander

Fluconazole (Diflucan)

Jin bu huan

Glyburide (Micronase)

Kava

Heparin

Scutellaria (skullcap)

Isoniazid (INH)

Senna

Ketoconazole (Nizoral)

Shark cartilage

Labetalol (Normodyne)

Vitamin A

Nitrofurantoin (Furadantin)

Nonsteroidal anti-inflammatory drugs

Phenytoin (Dilantin)

Protease inhibitors

Sulfonamides

Trazodone (Desyrel)


Information from reference 6.

The presence of other significant health conditions that can cause or augment liver transaminase elevations also should be noted; examples are diabetes, heart disease (including congestive heart failure), thyroid disease, muscle disease, and cancer. Physical findings and sequelae of liver dysfunction are given in Table 3.

TABLE 3

Clues in the Evaluation of Mildly Elevated Liver Transaminase Levels

Clinical clue Suggested diagnosis

Longstanding alcohol abuse

Cirrhosis

Intravenous drug use, history of blood product transfusions, nonsterile needle exposure, AST/ALT ratio < 1.0

Hepatitis B or C

Obesity, diabetes, hyperlipidemia, AST/ALT ratio < 1.0

Steatosis/steatohepatitis

AST/ALT ratio > 2.0

Alcoholic liver disease, Wilson’s disease

Increased iron levels

Hemochromatosis

Polypharmacy, illicit drug use, or certain herbal supplement use

Substance/medication-induced

Frequent, strenuous exercise

Exercise-induced

Intestinal bloating; oily, bulky stools

Celiac sprue

Hypergammaglobulinemia

Autoimmune hepatitis

Reduced ceruloplasmin levels, Kayser-Fleischer ring

Wilson’s disease

Depressed thyroid-stimulating hormone levels

Hyperthyroidism


ALT = alanine transaminase; AST = aspartate transaminase. [corrected]

TABLE 3   Clues in the Evaluation of Mildly Elevated Liver Transaminase Levels

View Table

TABLE 3

Clues in the Evaluation of Mildly Elevated Liver Transaminase Levels

Clinical clue Suggested diagnosis

Longstanding alcohol abuse

Cirrhosis

Intravenous drug use, history of blood product transfusions, nonsterile needle exposure, AST/ALT ratio < 1.0

Hepatitis B or C

Obesity, diabetes, hyperlipidemia, AST/ALT ratio < 1.0

Steatosis/steatohepatitis

AST/ALT ratio > 2.0

Alcoholic liver disease, Wilson’s disease

Increased iron levels

Hemochromatosis

Polypharmacy, illicit drug use, or certain herbal supplement use

Substance/medication-induced

Frequent, strenuous exercise

Exercise-induced

Intestinal bloating; oily, bulky stools

Celiac sprue

Hypergammaglobulinemia

Autoimmune hepatitis

Reduced ceruloplasmin levels, Kayser-Fleischer ring

Wilson’s disease

Depressed thyroid-stimulating hormone levels

Hyperthyroidism


ALT = alanine transaminase; AST = aspartate transaminase. [corrected]

Once the history and physical examination are completed, additional testing can help discern the etiology of the transaminase elevation (Figure 1).4

Management of Mild ALT and AST Abnormalities

Figure 1.

Algorithm to manage mild ALT and AST abnormalities. (ALT = alanine transaminase; AST = aspartate transaminase.)

Adapted with permission from American Gastroenterological Association. Medical position statement: evaluation of liver chemistry tests. Gastroenterology 2002; 123:1365.

View Large

Management of Mild ALT and AST Abnormalities


Figure 1.

Algorithm to manage mild ALT and AST abnormalities. (ALT = alanine transaminase; AST = aspartate transaminase.)

Adapted with permission from American Gastroenterological Association. Medical position statement: evaluation of liver chemistry tests. Gastroenterology 2002; 123:1365.

Management of Mild ALT and AST Abnormalities


Figure 1.

Algorithm to manage mild ALT and AST abnormalities. (ALT = alanine transaminase; AST = aspartate transaminase.)

Adapted with permission from American Gastroenterological Association. Medical position statement: evaluation of liver chemistry tests. Gastroenterology 2002; 123:1365.

INITIAL LABORATORY EVALUATION

Additional laboratory tests should be obtained when the history and physical examination show no obvious etiology for ALT and AST elevations. Ferritin, total iron-binding capacity, and serum iron can be used to look for hemochromatosis, while hepatitis A, B, and C serologies are used to rule out acute or chronic hepatitis.

Despite the emergence of widespread vaccination, hepatitis B remains a common cause of chronic liver disease in adults. Testing for hepatitis C is essential because its incidence has increased in the past decade, and new treatment strategies have been developed that can address this frequently missed problem.11

A prothrombin time (PT) and serum albumin should be ordered to identify patients with abnormalities of protein synthesis and liver function. Evaluation should be accelerated for patients with impaired hepatic synthetic function. A complete blood count with platelets also should be ordered. In addition to ruling out infection, neutropenia or thrombocytopenia can, along with an elevated PT, suggest advanced liver disease. An elevated mean red cell volume suggests heavy alcohol intake. Alkaline phosphatase and bilirubin are markers for hepatic cholestasis and should be ordered as part of the initial laboratory evaluation. While sometimes useful, they often are normal in the presence of hepatic injury.

LIFESTYLE MODIFICATION

If the patient is asymptomatic and the initial serum testing is negative, a period of lifestyle modification can be attempted. Effective lifestyle modification includes complete abstinence from alcohol, control of diabetes and hyperlipidemia, weight loss in overweight patients, and stopping or changing potentially hepatotoxic medications and supplements. Such lifestyle changes directly impact several of the causes of mild transaminase elevation (Table 1).5,6 These seemingly small modifications may be all that is needed to correct the abnormalities.

FOLLOW-UP AND IMAGING STUDIES

A repeat set of liver chemistries should be obtained after six months. If the patient’s presentation changes or the physician has concern for an evolving process, shorter intervals can be used. If abnormalities persist at the six-month follow-up visit, ultra-sonography of the liver is recommended. Computed tomography of the abdomen also is used in this setting, although clinical trials have not demonstrated an advantage of this more expensive modality.

Steatohepatitis (or nonalcoholic fatty liver disease) often is discovered by imaging. This condition may be the most frequent cause of mild liver chemistry elevations and is especially common in patients who are obese, and those who have diabetes or hyperlipidemia. One study12 of patients referred to a hospital-based gastroenterology practice found that in 83 percent of patients with elevated transaminase levels whose serum evaluation was otherwise negative, liver biopsy revealed steatosis or steatohepatitis. In 10 percent of the patients, however, liver biopsy was normal—a reminder that, at times, mildly elevated transaminase levels do not represent any underlying pathology. Excellent reviews of the management of nonalcoholic fatty liver disease have been published.13,14

If the diagnosis is not apparent from the ultrasound examination, further testing is suggested for alpha1-antitrypsin deficiency (alpha1-antitrypsin levels), Wilson’s disease (serum ceruloplasmin), celiac disease (antigliadin and anti-endomysial antibody), and autoimmune hepatitis (antinuclear antibody, anti–smooth-muscle antibody), as well as for nonhepatic causes of transaminase elevation. According to the AGA, the decision to perform a liver biopsy needs to be made on an individual basis, taking into consideration the patient’s age, lifestyle, liver chemistry abnormalities, desire for prognostic information, and associated comorbid conditions.1 Only with chronic mild transaminase elevations would an asymptomatic patient be considered a possible candidate for biopsy.

The Author

PAUL T. GIBONEY, M.D., is assistant professor of clinical family medicine at the Keck School of Medicine, University of Southern California, Los Angeles. He received his medical degree from Northwestern University School of Medicine, Chicago, and completed a residency in family medicine at John Peter Smith Hospital, Fort Worth, Tex.

Address correspondence to Paul T. Giboney, M.D., 123 S. Alvarado St., Los Angeles, CA 90057. Reprints are not available from the author.

The author indicates that he does not have any conflicts of interest. Sources of funding: none reported.

This article is one in a series on problem-oriented diagnosis coordinated by the Department of Family Medicine at the University of Southern California, Los Angeles.

 

REFERENCES

1. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123:1367–84.

2. Kundrotas LW, Clement DJ. Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. Dig Dis Sci. 1993;38:2145–50.

3. Sherwood P, Lyburn I, Brown S, Ryder S. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact. BMJ. 2001;322:276–8.

4. American Gastroenterological Association. Medical position statement: evaluation of liver chemistry tests. Gastroenterology. 2002;123:1364–6.

5. Davern TJ, Scharschmidt BF. Biochemical liver tests. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtran’s Gastrointestinal and liver disease: pathophysiology, diagnosis, management. 7th ed. Philadelphia: Saunders, 2002:1227–38.

6. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342:1266–71.

7. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94:1018–22.

8. Bayraktar M, Van Thiel DH. Abnormalities in measures of liver function and injury in thyroid disorders. Hepatogastroenterology. 1997;44:1614–8.

9. Bathum L, Petersen HC, Rosholm JU, Hyltoft Petersen P, Vaupel J, Christensen K. Evidence for a substantial genetic influence on biochemical liver function tests: results from a population-based Danish twin study. Clin Chem. 2001;47:81–7.

10. Yano E, Tagawa K, Yamaoka K, Mori M. Test validity of periodic liver function tests in a population of Japanese male bank employees. J Clin Epidemiol. 2001;54:945–51.

11. Kaur S, Rybicki L, Bacon BR, Gollan JL, Rustgi VK, Carey WD. Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: results from the National Hepatitis Screening Survey. Hepatology. 1996;24:979–86.

12. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol. 1999;94:3010–4.

13. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.

14. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis [published correction appears in Ann Intern Med 1997;127(8 pt 1):658]. Ann Intern Med. 1997;126:137–45.


Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article